HIF1A and neoplasm: Anti‐angiogenic therapies exacerbate this issue by impeding neovascularization, leading to regions of severe hypoxia.[40] However, previous studies have proposed that the therapeutic benefit of anti‐angiogenic agents may instead arise from vascular normalization, which alleviates hypoxia and improves tumor perfusion.[41, 42, 43, 44] Thus, to investigate whether lenvatinib treatment increases hypoxia within tumors, we assessed the levels of HIF‐1α with immunohistochemical staining.